QualityStocksNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has completed its spray-dried formulation and filling of the nasal device for its lead candidate, ONP-002, for the treatment of concussion. A new chemical entity, ONP-002 targets the brain through delivery into the nasal cavity. According to the announcement, the prefilled formulation will be used to provide dosing for the upcoming phase 2a clinical trial in concussed patients. “In preparing for the phase 2a study, we wanted to ensure that ONP-002 could be formulated as a nanoparticle and delivered intranasally as a…
